Clinical Trial

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 9, 2022 (before its estimated November 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types
Trial Details
NCT Number NCT05610332
Lead Sponsor Fujian Medical University
Conditions Locally Advanced Gastric Cancer
Enrollment 216 participants
Start Date 2022-11-01
Primary Completion 2024-11-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2022-11-09